Journal of Blood Disorders & Transfusion

How to deconstruct cancer one patient at the time: The wider application of the paradigm of haematological malignacies

2^nd International Conference on Hematology & Blood Disorders

September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Effie Liakopoulou

Keynote: J Blood Disorders Transf

Abstract:

Based on over 40 years of scientific, technological discovery and experience that there are better ways to treat cancer, a paradigm shift in diagnostics and clinical research is needed to ensure that new molecular insights are rapidly applied to shape emerging cancer therapies. Haematological malignancies have been a prime example of early phase of such approach leading to consequent benefit of other fields in oncology. Smarter and smaller clinical trials are necessary to capitalize on credible therapeutic signals and apply these to the treatment of early cancers for which major improvements in long term survival may be expected.

Biography :

Effie Liakopoulou is a physician scientist, specialist in Hematology Stem Cell Transplantation with particular interests in Hematological Oncology, Cell Therapies and Personalized Medicine. She holds MD and PhD degrees and a Certificate in Medical Management. She has 21 years of international experience and sound knowledge of the landscape in science, research and technology on clinical, medical and regulatory matters. Since 2006 she has served as inspector for the Joint Accreditation Committee - International Society for Cellular Therapy & European Group for Blood and Marrow Transplantation performing audits and due diligence of clinical, laboratory, research and specialist stem cell facilities. She is a member of several international professional organizations, and in 2009 she was elected Fellow of the Royal College of Pathologists, UK, in recognition of her contributions to the field of Hematology. She has co-authored several peer-reviewed publications and articles. Currently, she is an Affiliate Faculty Member in Hematology at, UW Medicine and Senior Research role for Retroscreen LTD. She is leading the coordination of due diligence in the academic, biotechnology and pharmaceutical arenas for technologies and fostering alliances for the advancement of Cancer therapies, Medicine and Health care as a whole.